Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:05:36.641Z.
Calculation as of: 2026-10-06T14:05:36.641Z.
Quote observation: 2026-10-06T14:04:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d88ebff11657cb0645ea93f74423bc241bf41286751ec96f31399ab1bd3406dc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Aprea Therapeutics, Inc.
Market Cap
$8.26M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $8.26M | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.58M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.94M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.53M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.83M | N/A |
| HeartSciences Inc. (HSCS)vs › | $7.34M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.46M | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.12M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.37M | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.22M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
